Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $217.4 million.

  • Revolution Medicines' Cash & Equivalents rose 803.93% to $217.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.4 million, marking a year-over-year increase of 803.93%. This contributed to the annual value of $543.1 million for FY2024, which is 2199.02% down from last year.
  • Revolution Medicines' Cash & Equivalents amounted to $217.4 million in Q3 2025, which was up 803.93% from $402.4 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Cash & Equivalents peaked at $696.1 million during Q4 2023, and registered a low of $97.7 million during Q1 2022.
  • In the last 5 years, Revolution Medicines' Cash & Equivalents had a median value of $275.7 million in 2024 and averaged $287.0 million.
  • In the last 5 years, Revolution Medicines' Cash & Equivalents surged by 71581.58% in 2021 and then crashed by 7222.17% in 2022.
  • Quarter analysis of 5 years shows Revolution Medicines' Cash & Equivalents stood at $108.5 million in 2021, then skyrocketed by 48.77% to $161.4 million in 2022, then surged by 331.29% to $696.1 million in 2023, then dropped by 21.99% to $543.1 million in 2024, then plummeted by 59.96% to $217.4 million in 2025.
  • Its Cash & Equivalents was $217.4 million in Q3 2025, compared to $402.4 million in Q2 2025 and $333.6 million in Q1 2025.